Tamsulosin, Solifenacin, and Their Combination for the Treatment of Stent-Related Symptoms: A Randomized Controlled Study.
To properly use the Ureteric Symptom Score Questionnaire (USSQ) to evaluate, in a randomized control study, the effect of tamsulosin, solifenacin, and their combination in improving symptoms and quality of life in patients with indwelling ureteral stents.



After institutional review board approval, 260 patients with a ureteral stent were randomly assigned to receive tamsulosin 0.4 mg, solifenacin 5 mg, or placebo and further randomized to receive their combination. The validated USSQ was completed 1 and 4 weeks after stent insertion and 4 weeks after stent removal. Kruskal-Wallis test, chi-squared test (or Fisher's exact test), one-way analysis of variance, and T-test (or Wilcoxon rank-sum test if not normal data) were used for statistical analysis. The results were considered significant at p < 0.05.



Patients receiving tamsulosin or solifenacin expressed significantly lower urinary (p < 0.001), pain (p < 0.001 with stent in situ), and general health index (p = 0.002 in first and p < 0.001 in fourth week with stent in situ) scores. Sexual life and quality of work were also positively influenced. Patients on combination therapy expressed lower urinary (p < 0.001) and pain (p < 0.001) scores in the fourth week with stent in situ and work performance in the first week and with stent in situ (p = 0.001) and after stent removal (p = 0.005). No patients had to discontinue medication due to side effects.



Stent-related morbidity is a reality in the majority of patients. Simple medication, such as tamsulosin and solifenacin alone or in combination, improves stent-related symptoms and has a positive impact on quality of life.
1 Second Department of Surgery, School of Medicine, Aretaieion Hospital, National and Kapodistrian University of Athens , Maroussi, Greece .
Athanasios E
AE
Dellis
2 Second Department of Urology, School of Medicine, Sismanogleion Hospital, National and Kapodistrian University of Athens , Maroussi, Greece .
Athanasios G
AG
Papatsoris
3 Southmead Hospital, Bristol Urological Institute , Bristol, United Kingdom .
Francis X
FX
Keeley
4 Department of Therapeutics, School of Medicine, Alexandra Hospital, National and Kapodistrian University of Athens , Athens, Greece .
Aristotelis
A
Bamias
2 Second Department of Urology, School of Medicine, Sismanogleion Hospital, National and Kapodistrian University of Athens , Maroussi, Greece .
Charalambos
C
Deliveliotis
2 Second Department of Urology, School of Medicine, Sismanogleion Hospital, National and Kapodistrian University of Athens , Maroussi, Greece .
Andreas A
AA
Skolarikos
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy; D010147:Pain Measurement; D011446:Prospective Studies; D011788:Quality of Life; D000069464:Solifenacin Succinate / Q000008:administration & dosage*; D015607:Stents / Q000009:adverse effects*; D013449:Sulfonamides / Q000008:administration & dosage*; D011795:Surveys and Questionnaires; D000077409:Tamsulosin; D014513:Ureter / Q000601:surgery; D064804:Urological Agents / Q000008:administration & dosage*; D055815:Young Adult
D013449:Sulfonamides; D064804:Urological Agents; D000077409:Tamsulosin; D000069464:Solifenacin Succinate
USSQ; solifenacin; stent-related symptoms; tamsulosin; ureteric stents